+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors



Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors



Pharmacological Reports 67(1): 44-51



This study aimed to investigate the effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats. We determined the pharmacokinetic parameters of nifedipine and dehydronifedipine in rats after oral and intravenous administration of nifedipine without and with HMG-CoA reductase inhibitors. We evaluated the effect of HMG-CoA reductase inhibitors on the activity of P-glycoprotein (P-gp) and cytochrome P450 (CYP)3A4. Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively. Simvastatin and fluvastatin increased the cellular uptake of rhodamine-123. The area under the plasma concentration-time curve (AUC0-∞) and the peak plasma concentration (Cmax) of oral nifedipine were significantly increased by fluvastatin and simvastatin, respectively, compared to control group. The total body clearance (CL/F) of nifedipine after oral administration with fluvastatin and simvastatin were significantly decreased compared to those of control. The metabolite-parent AUC ratio (MR) of nifedipine with fluvastatin and simvastatin were significantly decreased, which suggested that fluvastatin and simvastatin inhibited metabolism of nifedipine, respectively. The AUC0-∞ of intravenouse nifedipine with fluvastatin and simvastatin was significantly higher than that of the control group. The increased bioavailability of nifedipine may be mainly due to inhibition of both P-gp in the small intestine and CYP3A subfamily-mediated metabolism of nifedipine in the small intestine and/or in the liver and to the reduction of the CL/F of nifedipine by fluvastatin and simvastatin.

(PDF emailed within 0-6 h: $19.90)

Accession: 057719730

Download citation: RISBibTeXText

PMID: 25560574

DOI: 10.1016/j.pharep.2014.08.005


Related references

Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. Pharmacology 88(1-2): 1-9, 2012

Effects of nifedipine on the pharmacokinetics of repaglinide in rats: possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine. Pharmacological Reports 65(5): 1422-1430, 2014

Role of CYP3A4 and P-glycoprotein in drug interactions involving the HMG-CoA reductase inhibitors. Journal of the American Pharmaceutical Association 41(1): 5-6, 2001

Effects of licochalcone A on the bioavailability and pharmacokinetics of nifedipine in rats: possible role of intestinal CYP3A4 and P-gp inhibition by licochalcone A. Biopharmaceutics & Drug Disposition 35(7): 382-390, 2015

Similarities and differences in the inhibition of rat lens aldose reductase and kidney aldehyde reductase by aldose reductase inhibitors. Investigative Ophthalmology & Visual Science 30(3 SUPPL): 193, 1989

In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. European Journal of Clinical Pharmacology 50(3): 209-215, 1996

A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metabolism and Disposition: the Biological Fate of Chemicals 29(3): 282-288, 2001

Role of aldose reductase and effects of aldose reductase inhibitors in ocular tissue aging phenomena in the diabetic rat. Armstrong, D , M F Marmor And J M Ordy (Ed ) The Effects Of Aging And Environment on Vision; American Aging Association Symposium on Environmental Design For Optimum Vision in The Elderly, San Francisco, California, Usa, October 11-12, 1985 Viii+231p Plenum Press: New York, New York, Usa; London, Englannd, Uk Illus 121-131, 1991

Inhibition of aldehyde reductase by aldose reductase inhibitors. Biochemical Pharmacology 40(5): 1033-1042, 1990

Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases. American Journal of Cardiology 91(12A): 12H-18H, June 19, 2003

Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. British Journal of Clinical Pharmacology 65 Suppl 1: 38-46, 2008

Inhibition of naphthalene cataract in rats by aldose reductase inhibitors. Current Eye Research 15(4): 423-432, 1996

Effects of inhibitors for signaling components on the expression of the genes for nitrate reductase and nitrite reductase in excised barley leaves. Soil Science and Plant Nutrition 45(4): 1015-1019, 1999

The potential role of cyclooxygenase-2 inhibitors and 5alpha-reductase inhibitors in the prevention of urologic conditions. Urologic Clinics of North America 31(2): 213-218, 2004

Purified rat lens aldose reductase. Polyol production in vitro and its inhibition by aldose reductase inhibitors. Biochemical Journal 240(1): 233-237, 1986